Correlations of antibiotic use and carbapenem resistance in enterobacteriaceae

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 10, 2013, Pages 5131-5133

  McLaughlin, Milena ^a,b   Advincula, M Renee ^a   Malczynski, Michael ^b   Qi, Chao ^b,c   Bolon, Maureen ^b,c   Scheetz, Marc H ^a,b  

^a MIDWESTERN UNIVERSITY   (United States)

^b NORTHWESTERN MEMORIAL HOSPITAL   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAPENEM; ERTAPENEM; IMIPENEM; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; CARBAPENEM INTERMEDIATE RESISTANT ENTEROBACTERIACEAE; DISK DIFFUSION; DRUG EFFECT; DRUG USE; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTION; GRAM NEGATIVE BACTERIUM; HUMAN; INCIDENCE; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL; TREND STUDY;

ANTI-BACTERIAL AGENTS; CARBAPENEMS; DRUG RESISTANCE, FUNGAL; ENTEROBACTERIACEAE; MICROBIAL SENSITIVITY TESTS;

EID: 84884220511     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00607-13     Document Type: Article

References (17)

1. Cuzon G, Naas T, Truong H, Villegas MV, Wisell KT, Carmeli Y, Gales AC, Venezia SN, Quinn JP, Nordmann P. 2010. Worldwide diversity of Klebsiella pneumoniae that produce beta-lactamase blaKPC-2 gene. Emerg. Infect. Dis. 16:1349-1356.
2. Goren MG, Navon-Venezia S, Chmelnitsky I, Carmeli Y. 2010. Carbapenem- resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008. Antimicrob. Agents Chemother. 54:2687-2691.
3. Wendt C, Schutt S, Dalpke AH, Konrad M, Mieth M, Trierweiler-Hauke B, Weigand MA, Zimmermann S, Biehler K, Jonas D. 2010. First outbreak of Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae in Germany. Eur. J. Clin. Microbiol. Infect. Dis. 29:563-570.
4. Bratu S, Landman D, Alam M, Tolentino E, Quale J. 2005. Detection of KPC carbapenem-hydrolyzing enzymes in Enterobacter spp. from Brooklyn, New York. Antimicrob. Agents Chemother. 49:776-778.
5. Bratu S, Landman D, Haag R, Recco R, Eramo A, Alam M, Quale J. 2005. Rapid spread of carbapenem-resistant Klebsiella pneumoniae in New York City: a new threat to our antibiotic armamentarium. Arch. Intern. Med. 165:1430-1435.
6. Bratu S, Tolaney P, Karumudi U, Quale J, Mooty M, Nichani S, Landman D. 2005. Carbapenemase-producing Klebsiella pneumoniae in Brooklyn, NY: molecular epidemiology and in vitro activity of polymyxin B and other agents. J. Antimicrob. Chemother. 56:128-132.
7. Nordmann P, Dortet L, Poirel L. 2012. Carbapenem resistance in Enterobacteriaceae: here is the storm! Trends Mol. Med. 18:263-272.
8. Cao J, Song W, Gu B, Mei YN, Tang JP, Meng L, Yang CQ, Wang H, Zhou H. 2 February 2012. Correlation between carbapenem consumption and antimicrobial resistance rates of Acinetobacter baumannii in a university-affiliated hospital in China. J. Clin. Pharmacol. doi:10.1177 /0091270011435988. [Epub ahead of print.]
9. Goel N, Wattal C, Oberoi JK, Raveendran R, Datta S, Prasad KJ. 2011. Trend analysis of antimicrobial consumption and development of resistance in non-fermenters in a tertiary care hospital in Delhi, India. J. Antimicrob. Chemother. 66:1625-1630.
10. Iosifidis E, Antachopoulos C, Tsivitanidou M, Katragkou A, Farmaki E, Tsiakou M, Kyriazi T, Sofianou D, Roilides E. 2008. Differential correlation between rates of antimicrobial drug consumption and prevalence of antimicrobial resistance in a tertiary care hospital in Greece. Infect. Control Hosp. Epidemiol. 29:615-622.
11. Su CH, Wang JT, Hsiung CA, Chien LJ, Chi CL, Yu HT, Chang FY, Chang SC. 2012. Increase of carbapenem-resistant Acinetobacter baumannii infection in acute care hospitals in Taiwan: association with hospital antimicrobial usage. PLoS One 7:e37788. doi:10.1371/journal.pone .0037788.
12. Meyer E, Schwab F, Schroeren-Boersch B, Gastmeier P. 2010. Dramatic increase of third-generation cephalosporin-resistant E. coli in German intensive care units: secular trends in antibiotic drug use and bacterial resistance, 2001 to 2008. Crit. Care. 14:R113. doi:10.1186/cc9062.
13. Polk RE, Fox C, Mahoney A, Letcavage J, MacDougall C. 2007. Measurement of adult antibacterial drug use in 130 US hospitals: comparison of defined daily dose and days of therapy. Clin. Infect. Dis. 44:664-670.
14. Goossens H, Ghysels G, Van Laethem Y, De Wit S, Levy J, De Mol P, Clumeck N, Butzler JP, Wenzel RP. 1986. Predicting gentamicin resistance from annual usage in hospital. Lancet ii:804-805.
15. Sun L, Klein EY, Laxminarayan R. 2012. Seasonality and temporal correlation between community antibiotic use and resistance in the United States. Clin. Infect. Dis. 55:687-694.
16. Marchaim D, Chopra T, Bhargava A, Bogan C, Dhar S, Hayakawa K, Pogue JM, Bheemreddy S, Blunden C, Shango M, Swan J, Lephart PR, Perez F, Bonomo RA, Kaye KS. 2012. Recent exposure to antimicrobials and carbapenem-resistant Enterobacteriaceae: the role of antimicrobial stewardship. Infect. Control Hosp. Epidemiol. 33:817-830.
17. Patel N, Harrington S, Dihmess A, Woo B, Masoud R, Martis P, Fiorenza M, Graffunder E, Evans A, McNutt LA, Lodise TP. 2011. Clinical epidemiology of carbapenem-intermediate or -resistant Enterobacteriaceae. J. Antimicrob. Chemother. 66:1600-1608.